When evidence doesn't generalise: The case of ACE inhibition

The Lancet Diabetes and Endocrinology

Volumn 4, Issue 4, 2016, Pages 290-292

  Webster, Angela C ^a,b   Cross, Nicholas B ^c,d  

^a UNIVERSITY OF SYDNEY   (Australia)

^b WESTMEAD HOSPITAL   (Australia)

^c Department of Nephrology ^*  (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; RAMIPRIL;

CREATININE BLOOD LEVEL; END STAGE RENAL DISEASE; HUMAN; HYPERTENSION; KIDNEY TRANSPLANTATION; MORTALITY; NOTE; PRIORITY JOURNAL; PROTEINURIA;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; HUMANS;

EID: 84951085703     PISSN: 22138587     EISSN: 22138595     Source Type: Journal    
DOI: 10.1016/S2213-8587(15)00415-5     Document Type: Note

References (12)

1. Altman DG, Bland JM Generalisation and extrapolation. BMJ 1998, 317:409-410.
2. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev 2006, 4. CD006257.
3. Qaseem A, Hopkins RH, Sweet DE, Starkey M, Shekelle P Screening, monitoring, and treatment of stage 1 to 3 chronic kidney disease: a clinical practice guideline from the American College of Physicians. Ann Intern Med 2013, 159:835-847.
4. Cross NB, Webster AC, Masson P, O'Connell PJ, Craig JC Antihypertensive treatment for kidney transplant recipients. Cochrane Database Syst Rev 2009, 3. CD003598.
5. Halimi JM, Buchler M, Al-Najjar A, et al. Urinary albumin excretion and the risk of graft loss and death in proteinuric and non-proteinuric renal transplant recipients. Am J Transplant 2007, 7:618-625.
6. Opelz G, Zeier M, Laux G, Morath C, Dohler B No improvement of patient or graft survival in transplant recipients treated with angiotensin-converting enzyme inhibitors or angiotensin II type 1 receptor blockers: a collaborative transplant study report. J Am Soc Nephrol 2006, 17:3257-3262.
7. Knoll GA, Fergusson D, Chassé M, et al. Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial. Lancet Diabetes Endocrinol 2015, published online Oct 23. http://dx.doi.org/10.1016/S2213-8587(15)00368-X.
8. Hiremath S, Fergusson D, Doucette S, Mulay AV, Knoll GA Renin angiotensin system blockade in kidney transplantation: a systematic review of the evidence. Am J Transplant 2007, 7:2350-2360.
9. Kirkham JJ, Dwan KM, Altman DG, et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ 2010, 340:c365.
10. Masson P, Duthie FA, Ruster LP, et al. Consistency and completeness of reported outcomes in randomized trials of primary immunosuppression in kidney transplantation. Am J Transplant 2013, 13:2892-2901.
11. KDIGO clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 2009, 9:S1-155. KDIGO.
12. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010, 340:c869.